OBJECTIVE: To test the effects of emotionally expressive writing in a randomized controlled trial of metastatic breast cancer patients and to determine whether effects of the intervention varied as a function of perceived social support or time since metastatic diagnosis. DESIGN:Women (N = 62) living with Stage IV breast cancer were randomly assigned to write about cancer-related emotions (EMO; n = 31) or the facts of their diagnosis and treatment (CTL; n = 31). Participants wrote at home for four 20-min sessions within a 3-week interval. MAIN OUTCOME MEASURES: Depressive symptoms, cancer-related intrusive thoughts, somatic symptoms, and sleep quality at 3 months postintervention. RESULTS: No significant main effects of experimental condition were observed. A significant condition x social support interaction emerged on intrusive thoughts; EMO writing was associated with reduced intrusive thoughts for women reporting low emotional support (eta2 = .15). Significant condition x time since metastatic diagnosis interactions were also observed for somatic symptoms and sleep disturbances. Relative to CTL, EMO participants who were more recently diagnosed had fewer somatic symptoms (eta2 = .10), whereas EMO participants with longer diagnosis duration exhibited increases in sleep disturbances (eta2 = .09). CONCLUSION: Although there was no main effect of expressive writing on health among the current metastatic breast cancer sample, expressive writing may be beneficial for a subset of metastatic patients (including women with low levels of emotional support or who have been recently diagnosed) and contraindicated for others (i.e., those who have been living with the diagnosis for years). PsycINFO Database Record (c) 2010 APA, all rights reserved.
RCT Entities:
OBJECTIVE: To test the effects of emotionally expressive writing in a randomized controlled trial of metastatic breast cancerpatients and to determine whether effects of the intervention varied as a function of perceived social support or time since metastatic diagnosis. DESIGN:Women (N = 62) living with Stage IV breast cancer were randomly assigned to write about cancer-related emotions (EMO; n = 31) or the facts of their diagnosis and treatment (CTL; n = 31). Participants wrote at home for four 20-min sessions within a 3-week interval. MAIN OUTCOME MEASURES: Depressive symptoms, cancer-related intrusive thoughts, somatic symptoms, and sleep quality at 3 months postintervention. RESULTS: No significant main effects of experimental condition were observed. A significant condition x social support interaction emerged on intrusive thoughts; EMO writing was associated with reduced intrusive thoughts for women reporting low emotional support (eta2 = .15). Significant condition x time since metastatic diagnosis interactions were also observed for somatic symptoms and sleep disturbances. Relative to CTL, EMO participants who were more recently diagnosed had fewer somatic symptoms (eta2 = .10), whereas EMO participants with longer diagnosis duration exhibited increases in sleep disturbances (eta2 = .09). CONCLUSION: Although there was no main effect of expressive writing on health among the current metastatic breast cancer sample, expressive writing may be beneficial for a subset of metastatic patients (including women with low levels of emotional support or who have been recently diagnosed) and contraindicated for others (i.e., those who have been living with the diagnosis for years). PsycINFO Database Record (c) 2010 APA, all rights reserved.
Authors: Carl de Moor; Janet Sterner; Martica Hall; Carla Warneke; Zunera Gilani; Robert Amato; Lorenzo Cohen Journal: Health Psychol Date: 2002-11 Impact factor: 4.267
Authors: C Classen; L D Butler; C Koopman; E Miller; S DiMiceli; J Giese-Davis; P Fobair; R W Carlson; H C Kraemer; D Spiegel Journal: Arch Gen Psychiatry Date: 2001-05
Authors: Harriet J Rosenberg; Stanley D Rosenberg; Marc S Ernstoff; George L Wolford; Robert J Amdur; Mary R Elshamy; Susan M Bauer-Wu; Tim A Ahles; James W Pennebaker Journal: Int J Psychiatry Med Date: 2002 Impact factor: 1.210
Authors: Cheryl Koopman; Bita Nouriani; Vanessa Erickson; Renu Anupindi; Lisa D Butler; Michael H Bachmann; Sandra E Sephton; David Spiegel Journal: Breast J Date: 2002 Nov-Dec Impact factor: 2.431
Authors: Anne Moyer; Matthew Goldenberg; Matthew A Hall; Sarah K Knapp-Oliver; Stephanie J Sohl; Elizabeth A Sarma; Stefan Schneider Journal: Behav Med Date: 2012 Impact factor: 3.104
Authors: Catherine E Mosher; Katherine N Duhamel; Joanne Lam; Maura Dickler; Yuelin Li; Mary Jane Massie; Larry Norton Journal: Psychol Health Date: 2011-07-08
Authors: Birgitta Haga Gripsrud; Kelly J Brassil; Barbara Summers; Håvard Søiland; Steven Kronowitz; Kirsten Lode Journal: Cancer Nurs Date: 2016 Jul-Aug Impact factor: 2.592
Authors: Luana La Marca; Erika Maniscalco; Francesco Fabbiano; Francesco Verderame; Adriano Schimmenti Journal: Support Care Cancer Date: 2018-08-29 Impact factor: 3.603
Authors: Timothy J Williamson; Annette L Stanton; Jane E Austin; Heiddis B Valdimarsdottir; Lisa M Wu; Jennifer L Krull; Christine M Rini Journal: Ann Behav Med Date: 2017-10
Authors: Kathrin Milbury; Gabriel Lopez; Amy Spelman; Christopher Wood; Surena F Matin; Nizar M Tannir; Eric Jonasch; Louis Pisters; Qi Wei; Lorenzo Cohen Journal: Psychooncology Date: 2016-05-03 Impact factor: 3.894